case study: kapoose creek bio
Kapoose Creek Bio: From Functional Medicine Brand to AI-Powered Drug Discovery
How a brand built for a Canadian functional medicine launch carried a company through a strategic pivot — and now anchors a Genome Canada–funded drug discovery partnership with McMaster University.
The ChallengE
Kapoose Creek launched in 2020 as a Canadian functional medicine and psychedelics brand, founded by Vancouver music industry executive Sam Feldman. The original thesis: a consumer line of mushroom-powered Rx and OTC therapies at the intersection of functional medicine and emerging psilocybin science.
The brief was difficult by design. The brand had to be credible to cautious regulators, calming to first-time consumers, premium enough to justify therapeutic pricing, and serious enough that research scientists, healthcare professionals, and biotech investors would take the company seriously.
The visual category had collapsed into two competing clichés. Psychedelic nostalgia (mandalas, gradients, cosmic imagery) felt unserious for serious science. Clinical sterility (white packaging, pharmaceutical photography) felt cold to consumers seeking healing. The brand had to be a third thing entirely.
The Strategic InsighT
We made one bet that mattered more than any other design decision: we built the brand to look like a serious bio company that happened to have a consumer line — rather than a consumer brand pretending to be scientific.
The visual language pulled from editorial publishing, heritage apothecary, and academic journals. Not wellness CPG. Not psychedelic culture. The intent was to give the company optionality — to ensure that if Kapoose Creek ever needed to present itself to a regulator, a research partner, or a board of biotech directors, the brand would already speak that room's language.
At the time, we didn't know how much that bet would matter.
The SolutioN
We built the brand around a single visual metaphor: the hero's journey. The logo — a creek and mountain ridge forming a mushroom — anchored every touchpoint with quiet symbolic weight. The color system was earthen and clinical-adjacent: terracotta, dried mushroom, parchment, deep forest. Typography pulled from editorial publishing and academic journals rather than wellness CPG.
Packaging architecture treated each product as a dose of something significant, not a recreational item. Every element — typography, color, material, hierarchy — was calibrated to communicate seriousness without sterility, intention without intimidation.
Critically, the brand system was designed to extend beyond consumer packaging from day one. The same visual language carried into corporate identity, partnership communications, and investor materials. The brand wasn't a CPG skin laid over a company. It was the visual operating system of an organization preparing for multiple possible futures.
The OUTCOME
In April 2023, the company made a strategic decision that would change everything about the business — but very little about the brand. The board concluded that the commercial case for a psilocybin-era consumer line had eroded. The company rebranded from Kapoose Creek Wellness to Kapoose Creek Bio, restructured its board with biotech veterans, and sharpened its focus toward AI-powered drug discovery.
The brand survived the pivot intact — and opened doors no one had anticipated:
C$2.2M drug discovery partnership with McMaster University and Genome Canada, announced May 2024, funded through the Genomic Applications Partnership Program (GAPP) — co-led by CEO Dr. Eric Brown (FRSC, Distinguished University Professor, McMaster) and Dr. Gerry Wright (2024 Killam Prize in Health Sciences).
Lead compound KCB-100 — a fungal metabolite in preclinical development for major depressive disorder and neurodegenerative disease — earned its lead researcher, Dr. Timsy Bhando, a 2024 Mitacs Innovation Award for Outstanding Innovation, one of only four conferred nationally.
Acquisition of Adapsyn Bioscience (October 2024), bringing in an AI-powered drug discovery platform, four scientists, and a fully-equipped chemistry lab at McMaster Innovation Park.
Board expansion to include Dr. Stewart Fisher, the recently retired Chief Scientific Officer of Boston-listed C4 Therapeutics.
Coverage in BC Business, Drug Target Review, BIOTECanada Insights, Life Sciences BC, and McMaster's Brighter World.
A brand built well doesn't just sell the thing it was originally designed to sell. It earns the company permission to become something bigger.
"The brand built for a functional medicine launch became the visual foundation for a biotech pivot — and now anchors a $2.2M Genome Canada–funded drug discovery partnership with McMaster University."
more case studies
Clarity creates momentum
Every project is built to solve a business problem. We help companies become more recognizable, more trusted, and more valuable in the eyes of their customers.
07 HOW IT WORKS
Senior Brand Leadership. On Subscription.
